Research Article
Follow-Up of Advanced Parkinson’s Disease Patients after Clinical or Surgical Emergencies: A Practical Approach
Table 1
Characteristics of advanced PD patients with clinical or surgical complications.
| | Variable | Before hospitalization | After hospitalization | |
| | Gender—male (%) | 8 (61.5) | — | — | | Age, years ± SD | 76.8 ± 3.5 | — | — | | Disease duration, years ± SD | 15.8 ± 2.4 | — | — | | Hospital stay | 16.4 ± 5.7 | — | — | | Mean daily levodopa dose (mg) | 907.7 ± 149.8 | 1061.5 ± 175.8 | <0.0001 | | Mean daily LED (mg) | 1202.1 ± 197.1 | 1371.2 ± 219.4 | <0.0001 | | UPDRS | 39.8 ± 2.7 | 51.5 ± 3.3 | <0.0001 | | Cognitive dysfunction, n (%) | 13 (100) | 13 (100) | | | PD-MCI, n (%) | 5 (38.5) | 5 (38.5) | 1 | | PD dementia, n (%) | 8 (61.5) | 8 (61.5) | | | Mean daily rivastigmine patch dose (mg) | 7.9 ± 2.9 | 7.9 ± 2.9 | 1 |
|
|
PD: Parkinson’s disease; SD: standard deviation; LED: levodopa equivalent dose; UPDRS: Unified Parkinson’s Disease Rating Scale: MCI: mild cognitive impairment.
∗Student's t test. Values of p <0.05 indicate statistical significance.
|
